A new study finds that the weight-loss drug Ozempic may help stroke patients reduce their risk of heart attack or death. Researchers revealed that GLP-1 weight loss drugs like Ozempic or SGLT2 diabetes drugs like Jardiance or Farxiga could help protect people after stroke. The study’s findings were presented at the American Heart Association’s annual meeting in Chicago and have not yet been published in a peer-reviewed journal.

According to a report by US News, study results showed that patients taking GLP-1 or SGLT2 drugs had a 74% lower risk of death and an 84% lower risk of heart attack within an average of three years after a stroke. . , The study also says SGLT2 drugs were associated with a 67% lower risk of a second stroke.

“Unfortunately, about a quarter of stroke survivors will have a second stroke, and they are also at risk for other cardiovascular events,” said lead researcher Dr. Ali Shefeh, an internal medicine physician and research scholar at the Mayo Clinic in Rochester, Minnesota. Are.” Such as heart attack because many of the risk factors for stroke are also associated with other forms of heart disease.”

“Looking at new approaches to help manage these risks as well as reduce the chances of another stroke, heart attack or death among this population is critical to improving stroke survival and prolonging life,” Sheffeh said in a news release. “All important steps to improve quality.” “People who have had a stroke.”

For the study, researchers reviewed the medical records of more than 7,000 adults treated for strokes caused by blood clots between January 2000 and June 2022 in Minnesota or Wisconsin. The team looked specifically at the potential benefits that taking GLP-1 or SGLT2 drugs could have after stroke.

The researchers found that the death rate was less than 12% in stroke survivors who took GLP-1 or SGLT2 drugs, compared to 54% in patients who did not take either drug. The heart attack rate in patients taking any of these drugs was 1.5%, while the heart attack rate in patients not taking any of these drugs was 6%.

“The study results are consistent with other research about the preventive role of these drugs against heart disease in people with obesity or heart failure,” Shefeh said.

Dr. Cheryl Bushnell, vice chair of neurology research at Wake Forest University School of Medicine in Winston-Salem, N.C., said in a news release, “For several years, we have seen from randomized controlled trials that SGLT2 inhibitors and GLP-1 receptor agonists have “Has the potential to reduce the risk of cardiovascular disease, including stroke, heart attack, and death.”

“These new findings are in line with what we expected, and we have seen that these results are evident in patients with type 2 diabetes and obesity and in patients with obesity without type 2 diabetes,” Bushnell said.

Get the latest news live on Times Now with breaking news and top headlines from around the world.